Literature DB >> 357055

Inhibition of polyclonal B-cell activation by suppressor monocytes in patients with sarcoidosis.

P Katz, A S Fauci.   

Abstract

The present study employed a direct plaque-forming cell (PGC) assay following pokeweed mitogen (PWM) induced polyclonal activation of B lymphocytes in sarcoidosis to evaluate the in vitro humoral immune response in this disease and to delineate the immunoregulation of this response. Sarcoidosis lymphocytes had a suppressed PFC response to polyclonal activation, but were unable to suppress normal B-cell PFC responses in allogeneic co-cultures. Removal of a cell type, which was corticosteroid-resistant, radio-resistant, adherent and a non-T cell, from sarcoidosis mononuclear cell suspensions reversed the suppressed PFC response, indicating the presence of a suppressor monocyte. Thus in vitro suppressor cell activity has now been demonstrated in this disease, which is characterized by multiple immunological aberrancies.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 357055      PMCID： PMC1541315     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  24 in total

1.  IN-VITRO STUDIES OF LYMPHOCYTES FROM PATIENTS WITH SARCOIDOSIS AND LYMPHOPROLIFERATIVE DISEASES.

Authors:  K HIRSCHHORN; R R SCHREIBMAN; F H BACH; L E SILTZBACH
Journal:  Lancet       Date:  1964-10-17       Impact factor: 79.321

2.  Activation of human B lymphocytes. III. Concanavalin A-induced generation of suppressor cells of the plaque-forming cell response of normal human B lymphocytes.

Authors:  B F Haynes; A S Fauci
Journal:  J Immunol       Date:  1977-06       Impact factor: 5.422

3.  Role of suppressor T cells in pathogenesis of common variable hypogammaglobulinaemia.

Authors:  T A Waldmann; M Durm; S Broder; M Blackman; R M Blaese; W Strober
Journal:  Lancet       Date:  1974-09-14       Impact factor: 79.321

4.  Enhancement by irradiated T cells of human plasma cell production: dissection of helper and suppressor functions in vitro.

Authors:  F P Siegal; M Siegal
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

5.  Activation of human B lymphocytes. II. Cellular interactions in the PFC response of human tonsillar and peripheral blood B lymphocytes to polyclonal activation by pokeweed mitogen.

Authors:  A S Fauci; K R Pratt; G Whalen
Journal:  J Immunol       Date:  1976-12       Impact factor: 5.422

6.  Polyclonal activation of bone-marrow-derived lymphocytes from human peripheral blood measured by a direct plaque-forming cell assay.

Authors:  A S Fauci; K R Pratt
Journal:  Proc Natl Acad Sci U S A       Date:  1976-10       Impact factor: 11.205

7.  Activation of human B lymphocytes. IV. Regulatory effects of corticosteroids on the triggering signal in the plaque-forming cell response of human peripheral blood B lymphocytes to polyclonal activation.

Authors:  A S Fauci; K R Pratt; G Whalen
Journal:  J Immunol       Date:  1977-08       Impact factor: 5.422

8.  Monocyte IgG receptor activity, dynamics, and modulation-normal individuals and patients with granulomatous diseases.

Authors:  M E Schmidt; S D Douglas
Journal:  J Lab Clin Med       Date:  1977-02

9.  Suppression of lymphoproliferation by high concentrations of normal human mononuclear leukocytes.

Authors:  A H Laughter; J J Twomey
Journal:  J Immunol       Date:  1977-07       Impact factor: 5.422

10.  Functional analysis of two human T-cell subpopulations: help and suppression of B-cell responses by T cells bearing receptors for IgM or IgG.

Authors:  L Moretta; S R Webb; C E Grossi; P M Lydyard; M D Cooper
Journal:  J Exp Med       Date:  1977-07-01       Impact factor: 14.307
View more
  19 in total

1.  Immune defects in chronic renal impairment: evidence for defective regulation of lymphocyte response by macrophages from patients with chronic renal impairment on haemodialysis.

Authors:  N D Tsakolos; T C Theoharides; E D Hendler; J Goffinet; J M Dwyer; R L Whisler; P W Askenase
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

2.  Impaired primary in-vitro antibody response in progressive systemic sclerosis patients: rôle of suppressor monocytes.

Authors:  P Segond; D Salliere; P Galanaud; R M Desmottes; P Massias; J N Fiessinger
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

3.  Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers.

Authors:  G M Dusheiko; J H Hoofnagle; W G Cooksley; S P James; E A Jones
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

4.  Characterization of a non-T, non-B human lymphocyte (L cell) with use of monoclonal antibodies. Its regulatory role in B lymphocyte function.

Authors:  P I Lobo
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

5.  Decreased in vitro humoral immune responses in aged humans.

Authors:  S G Pahwa; R N Pahwa; R A Good
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

6.  Immunocompetent cells and delayed hypersensitivity reaction in sarcoidosis.

Authors:  A Arnoux; G Stanislas-Leguern; J Marsac; J Chretien
Journal:  Lung       Date:  1981       Impact factor: 2.584

7.  Disturbed homeostasis and multiple signaling defects in the peripheral blood B-cell compartment of patients with severe chronic sarcoidosis.

Authors:  Nam-Sihk Lee; Laura Barber; Shaw M Akula; George Sigounas; Yash P Kataria; Sergio Arce
Journal:  Clin Vaccine Immunol       Date:  2011-06-08

Review 8.  Pathogenesis of sarcoidosis.

Authors:  K Van Gundy; O P Sharma
Journal:  West J Med       Date:  1987-08

9.  Demonstration of non-specific B-cell stimulation in patients with cirrhosis.

Authors:  G Holdstock; W B Ershler; E L Krawitt
Journal:  Gut       Date:  1982-09       Impact factor: 23.059

10.  Studies of peripheral blood monocytes in pulmonary sarcoidosis.

Authors:  F K Rømer; S E Christiansen; K Kragballe; T Herlin; M Madsen
Journal:  Clin Exp Immunol       Date:  1984-11       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.